Merck falls 7% despite an earnings beat as a pipeline setback and Gardasil weakness act as dampeners. However, Keytruda and new launches support growth.

Merck’s MRK strong oncology sales growth is largely driven by its biggest revenue driver, Keytruda. The blockbuster PD-L1 ...

Erasca (ERAS) on Monday announced a clinical trial collaboration and supply agreement (CTCSA) with Merck (MRK), known as MSD ...

(Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today ...

Adding Inhibrx Biosciences’ OX40 agonist to Keytruda doubled the response rate in a midphase clinical trial, encouraging the ...

Merck’s MRK strong foothold in the oncology space is propelled by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor alone accounted for more than 50% of the company’s ...

Merck highlights new long-term data and advancements across broad oncology portfolio and pipeline research at ASCO 2026: Rahway, New Jersey Wednesday, May 13, 2026, 11:00 Hrs [IST ...

Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best Biotech Stocks to Invest In According to Billionaire Steve Cohen. On April ...

Merck is scheduled to report first-quarter earnings on April 30, during market hours, with analysts expecting a strong performance from Keytruda and Winrevair.

Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable locally advanced head and neck cancer. But the breakthrough approval comes ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and Lenvima didn’t exactly go their way. The Keytruda-Lenvima regimen, used on top ...

Merck & Co., Inc. (NYSE:MRK) is a global health care company working to deliver innovative health solutions through our ...